Evidence map›Paper›PMID 42363837›Full record

ArticleAntimicrobial agents and chemotherapy2026

Identification of key metabolic enzymes involved in the activation of obeldesivir and remdesivir to the active triphosphate metabolite.

Yili Xu, Albert Liclican, Xiaofeng Zhao, Chen Chen, Joseph T Ortega, Hsiu-Chun Chuang, Cameron Soulette, Subhra Chaudhuri, Jingyu Zhang, Ting Wang and 16 more

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Yili XuGilead Sciences, Inc., Foster City, California, USA.ORCID 0000-0002-0083-799X
Albert LiclicanGilead Sciences, Inc., Foster City, California, USA.
Xiaofeng ZhaoGilead Sciences, Inc., Foster City, California, USA.
Chen ChenGilead Sciences, Inc., Foster City, California, USA.
Joseph T OrtegaGilead Sciences, Inc., Foster City, California, USA.
Hsiu-Chun ChuangGilead Sciences, Inc., Foster City, California, USA.
Cameron SouletteGilead Sciences, Inc., Foster City, California, USA.
Subhra ChaudhuriGilead Sciences, Inc., Foster City, California, USA.
Jingyu ZhangGilead Sciences, Inc., Foster City, California, USA.
Ting WangGilead Sciences, Inc., Foster City, California, USA.
Darius BabusisGilead Sciences, Inc., Foster City, California, USA.
Bruno MarchandGilead Sciences, Inc., Foster City, California, USA.
Kai-Hui SunGilead Sciences, Inc., Foster City, California, USA.
Ricardo RamirezGilead Sciences, Inc., Foster City, California, USA.ORCID 0000-0003-1668-6230
Bin MaGilead Sciences, Inc., Foster City, California, USA.
Arabinda NayakGilead Sciences, Inc., Foster City, California, USA.
Liya WangDepartment of Animal Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden.
Saurabh MenonGilead Sciences, Inc., Foster City, California, USA.
Jean-Philippe BelzileGilead Sciences, Inc., Foster City, California, USA.
Yurong LaiGilead Sciences, Inc., Foster City, California, USA.
Li LiGilead Sciences, Inc., Foster City, California, USA.ORCID 0000-0002-7171-6271
Richard L MackmanGilead Sciences, Inc., Foster City, California, USA.
John P BilelloGilead Sciences, Inc., Foster City, California, USA.
Tomas CihlarGilead Sciences, Inc., Foster City, California, USA.
Joy Y FengGilead Sciences, Inc., Foster City, California, USA.
Latesh LadGilead Sciences, Inc., Foster City, California, USA.ORCID 0009-0001-2238-6704

Funding

Gilead Sciences
6 · The paper itself

Abstract

Obeldesivir (GS-5245, ODV), an orally administered 5'-isobutyryl ester prodrug of GS-441524, has demonstrated anti-SARS-CoV-2 activity in preclinical and clinical settings. ODV is hydrolyzed in plasma to provide high systemic exposures of GS-441524, enabling the efficient intracellular formation of the bioactive 5'-triphosphate GS-443902, an ATP analog inhibiting the SARS-CoV-2 RNA-dependent RNA polymerases. Remdesivir (RDV), the first US FDA-approved antiviral treatment for COVID-19, is also activated to GS-443902. In this paper, we systematically profiled the human enzymes potentially involved in ODV and RDV activation using multiple approaches: (i) biochemical studies on the catalytic efficiency (

Indexed as

Adenosine MonophosphateAlanineAntiviral AgentsAdenosineAdenosine TriphosphateCOVID-19 Drug TreatmentHumansProdrugsSARS-CoV-2AdenosineAdenosine MonophosphateAdenosine TriphosphateAlanineAntiviral AgentsGS-441524GS-441524 triphosphateProdrugsremdesiviractivation pathwayGS-441524obeldesivirODVphosphotransferases

Identifiers

PMID42363837
PMCPMC13436262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.